176 related articles for article (PubMed ID: 30513960)
21. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
22. Analysis of ABC (D) stratification for screening patients with gastric cancer.
Kudo T; Kakizaki S; Sohara N; Onozato Y; Okamura S; Inui Y; Mori M
World J Gastroenterol; 2011 Nov; 17(43):4793-8. PubMed ID: 22147980
[TBL] [Abstract][Full Text] [Related]
23. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study.
So JB; Yeoh KG; Moochala S; Chachlani N; Ho J; Wong WK; Mack P; Goh PM
Gastric Cancer; 2002; 5(4):228-32. PubMed ID: 12491081
[TBL] [Abstract][Full Text] [Related]
24. Significance of Serological Gastric Biopsy in Different Gastric Mucosal Lesions: an Observational Study.
Dong Z; Zhang X; Chen X; Zhang J
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31414587
[TBL] [Abstract][Full Text] [Related]
25. Pepsinogen test for the evaluation of precancerous changes in gastric mucosa: a population-based study.
Sjomina O; Pavlova J; Daugule I; Janovic P; Kikuste I; Vanags A; Tolmanis I; Rudzite D; Polaka I; Kojalo I; Liepniece-Karele I; Isajevs S; Santare D; Pirags V; Pahomova J; Dzerve V; Tzivian L; Erglis A; Leja M
J Gastrointestin Liver Dis; 2018 Mar; 27(1):11-17. PubMed ID: 29557410
[TBL] [Abstract][Full Text] [Related]
26. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer.
Tsai YC; Hsiao WH; Yang HB; Cheng HC; Chang WL; Lu CC; Sheu BS
Aliment Pharmacol Ther; 2013 May; 37(10):969-78. PubMed ID: 23550594
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
[TBL] [Abstract][Full Text] [Related]
28. Histological Features of Gastric Mucosa Serologically Diagnosed as Gastric Atrophy without Helicobacter pylori Infection.
Okuno H; Suzuki S; Watanabe H; Kusano C; Ikehara H; Moriyama M; Gotoda T
Digestion; 2020; 101(2):217-226. PubMed ID: 30870847
[TBL] [Abstract][Full Text] [Related]
29. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.
Ikeda F; Shikata K; Hata J; Fukuhara M; Hirakawa Y; Ohara T; Mukai N; Nagata M; Yoshida D; Yonemoto K; Esaki M; Kitazono T; Kiyohara Y; Ninomiya T
J Epidemiol; 2016 Dec; 26(12):629-636. PubMed ID: 27265836
[TBL] [Abstract][Full Text] [Related]
30. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages.
Kim YI; Kook MC; Cho SJ; Lee JY; Kim CG; Joo J; Choi IJ
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28940945
[TBL] [Abstract][Full Text] [Related]
31. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.
Aikou S; Ohmoto Y; Gunji T; Matsuhashi N; Ohtsu H; Miura H; Kubota K; Yamagata Y; Seto Y; Nakajima A; Goldenring JR; Kaminishi M; Nomura S
Gastroenterology; 2011 Sep; 141(3):837-845.e1-7. PubMed ID: 21699780
[TBL] [Abstract][Full Text] [Related]
32. OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications.
Mansour-Ghanaei F; Joukar F; Yeganeh S; Sadeghi M; Daryakar A; Sepehrimanesh M
Turk J Gastroenterol; 2022 Feb; 33(2):95-102. PubMed ID: 35238779
[TBL] [Abstract][Full Text] [Related]
33. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
34. Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer.
Kishino T; Oyama T; Tomori A; Takahashi A; Shinohara T
Intern Med; 2020 Jun; 59(12):1473-1480. PubMed ID: 32188803
[TBL] [Abstract][Full Text] [Related]
35. Clinical correlation between serum pepsinogen level and gastric atrophy in gastric neoplasm.
Cha JH; Jang JS
Korean J Intern Med; 2020 Apr; 35(3):550-558. PubMed ID: 30400679
[TBL] [Abstract][Full Text] [Related]
36. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.
Sugiu K; Kamada T; Ito M; Kaya S; Tanaka A; Kusunoki H; Hata J; Haruma K
Dig Liver Dis; 2006 May; 38(5):303-7. PubMed ID: 16549394
[TBL] [Abstract][Full Text] [Related]
37.
Wu M; Feng S; Qian M; Wang S; Zhang K
Risk Manag Healthc Policy; 2022; 15():2243-2255. PubMed ID: 36475275
[TBL] [Abstract][Full Text] [Related]
38. Population based Helicobacter pylori screening and eradication: advances versus side effects.
Tepes B
Curr Pharm Des; 2014; 20(28):4501-9. PubMed ID: 24180403
[TBL] [Abstract][Full Text] [Related]
39. Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais.
Yamada S; Matsuhisa T; Makonkawkeyoon L; Chaidatch S; Kato S; Matsukura N
J Gastroenterol; 2006 Dec; 41(12):1169-77. PubMed ID: 17287896
[TBL] [Abstract][Full Text] [Related]
40. Biopsy strategies for endoscopic screening of pre-malignant gastric lesions.
Zhang M; Liu S; Hu Y; Bao HB; Meng LN; Wang XT; Xu Y; Zhao J; Lu B
Sci Rep; 2019 Oct; 9(1):14909. PubMed ID: 31624309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
